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Introduction
Falls are a key consequence of the frailty syndrome, and 
hip fracture is a particularly feared consequence of falling. 
Controversy continues in the extent to which antihypertensive 
medication might contribute to falls risk; such medications 
are frequently stopped in older people who fall because of 
a perception that such medications increase falls risk by 
reducing blood pressure and hence cerebral perfusion. However 
some classes of medication, notably angiotensin-converting 
enzyme inhibitors (ACEi) and angiotensin receptor blockers 
(ARBs) have been shown to have beneficial effects on muscle 
function in preclinical and some clinical studies (1-4). This 
raises the possibility that such medications could in fact 
be protective against falls, with recent systematic reviews 
supporting this possibility (5). There is currently uncertainty 
from observational studies as to whether ACEi and ARBs 
reduce or increase the risk of fractures, in part because analyses 
to date have not been able to adjust for functional status at 
baseline (6-13). In addition, some studies have not been able to 
account for cumulative exposure to these medications, instead 
restricting analyses to baseline exposure with consequent 
indication bias. The aim of this analysis was therefore to test 
the association between ACEi / ARB use and hip fracture 
using a large, routinely collected, linked health and social care 
dataset.
Methods
We performed a retrospective analysis of linked routinely-
collected health and social care data. We studied patients aged 
65 and over within the Tayside health board area, Scotland, 
UK (population 400,000), who had contact with Dundee city 
council social services between 2002 and 2012. The date of first 
social services assessment was taken as the inception date for 
each individual in the analysis cohort. We derived cumulative 
exposure to ACEi or ARB (in days) and any exposure including 
prior to the inception date from community prescribing records 
of prescriptions that were encashed with pharmacists. Deaths 
were obtained from Scottish General Register Office records. 
Hip fractures and comorbidity diagnoses were derived from 
hospital discharge records using ICD-10 codes. Hip fracture 
was diagnosed by the presence of ICD-10 codes S72.0, 
S72.1, S72.2, S72.8 or S72.9. Biochemical covariates were 
obtained from routinely collected biochemistry data analysed 
at Ninewells Hospital, Dundee. The need for a care package 
was used as a proxy for functional impairment; these data were 
obtained from Dundee City Council social work records. The 
methods used for sourcing and assembling these linked data 
have been described previously (14). All data were held with 
the Dundee Health Informatics Centre safe haven environment. 
Local Caldicott Guardian (data protection officer) approval 
was in place for all studies involving this linked dataset; the 
need for research ethics approval was waived as the analysis 
was performed using data collected as part of routine clinical 
care with no additional patient contact, which had then been 
anonymised prior to release to the research team.
ASSOCIATION BETWEEN THE USE OF ANGIOTENSIN-BLOCKING 
MEDICATIONS WITH HIP FRACTURE AND DEATH IN OLDER PEOPLE   
C. SHEA1, M.D. WITHAM1,2
1. School of Medicine, University of Dundee, Dundee, United Kingdom; 2. AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle 
upon Tyne Hospitals Trust, Newcastle, United Kingdom
Corresponding author: Professor Miles Witham, AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle NE4 5PL, UK.  
Email: Miles.Witham@newcastle.ac.uk. Tel: 0044 191 208 1317
Abstract: It is unclear if angiotensin blocking drugs (angiotensin converting enzyme inhibitors and angiotensin 
receptor blockers) reduce or increase the risk of falls and fractures. We retrospectively analysed routinely-
collected, linked health and social care data for patients aged 65 and over from Tayside, Scotland, including 
hospital discharge diagnoses, biochemistry, deaths, care package provision and community prescribing. We 
conducted unadjusted and adjusted Cox regression analyses for time to hip fracture and time to death, for any 
exposure to angiotensin blocking drugs and for time-dependent exposure to angiotensin blocking drugs. We 
analysed data on 16782 patients. Angiotensin blocking drug use was associated with an exposure-dependent 
lower risk of hip fracture (hazard ratio 0.988 [95%CI 0.982-0.994] per year of exposure; p<0.001) and death 
(hazard ratio 0.986 [95%CI 0.983-0.989] per year of exposure; p<0.001). These findings call into question the 
appropriateness of stopping angiotensin blocking drugs for older people at risk of falls.
Key words: Hip fracture, ACE inhibitor, angiotensin receptor blocker, mortality.
J Frailty Aging 2019;in press
Published online October 30, 2019, http://dx.doi.org/10.14283/jfa.2019.38
© The Author(s)
ASSOCIATION BETWEEN THE USE OF ANGIOTENSIN-BLOCKING MEDICATIONS WITH HIP FRACTURE AND DEATH 
The Journal of Frailty & Aging
2
We conducted unadjusted and adjusted Cox regression 
analyses for time to hip fracture and time to death, starting with 
any previous exposure to ACEi/ARB and then adding time-
dependent exposure to ACEi/ARB. Such an approach allows 
the effect of drug exposure to be at least partly separated from 
the presence of the drug as a marker of underlying disease. 
Although hip fracture was our primary outcome of interest, 
we analysed all-cause mortality as well to ensure that any 
benefit on hip fracture was not counterbalanced by an adverse 
effect on mortality rates. We additionally conducted competing 
risks analysis using the method of Fine and Gray (15) to test 
whether accounting for all-cause mortality as a competing 
risk modified the association between ACEi/ARB use and 
hip fracture. Analyses were adjusted for baseline age, sex, 
deprivation, comorbidities, previous hip fracture, creatinine, 
bisphosphonate therapy, calcium and vitamin D therapy and 
receipt of a care package as a proxy for impaired physical 
function. These factors were chosen as they were available 
Table 1
Baseline details of analysis cohort
Never on ACEi or ARB n=8428 ACEi or ARB use n=8354 P
Mean age (years) (SD) 73.5 (9.4) 73.8 (8.4) 0.05
Female (%) 5146 (61.1) 4811 (57.6) <0.001
Decile of deprivation (SD) 5.4 (3.0) 5.0 (3.0) <0.001
Previous myocardial infarction (%) 257 (3.0) 1189 (14.2) <0.001
Previous stroke (%) 307 (3.6) 733 (8.8) <0.001
Congestive heart failure (%) 219 (2.6) 761 (9.1) <0.001
Chronic obstructive pulmonary disease (%) 546 (6.5) 609 (7.3) 0.038
Diabetes mellitus (%) 506 (6.0) 1730 (20.7) <0.001
Previous hip fracture (%) 317 (3.8) 225 (2.7) <0.001
Mean creatinine (μmol/l) (SD) 91 (55) 101 (61) <0.001
Bisphosphonate therapy (%) 379 (4.5) 397 (4.8) 0.43
Calcium / Vitamin D therapy (%) 505 (6.0) 566 (6.8) 0.038
Current care package (%) 543 (6.4) 676 (8.1) <0.001
Died during follow up (%) 2534 (30.1) 1699 (20.3) <0.001
New hip fracture (%) 390 (4.6) 255 (3.1) <0.001
ACEi: Angiotensin converting enzyme inhibitor. ARB: Angiotensin receptor blocker
Table 2
Cox proportional hazards models showing effect of ACEi / ARB exposure on risk of hip fracture or death
Hip fracture 
Hazard ratio 
(95% CI)
P All-cause death 
Hazard ratio 
(95% CI)
P
Previously exposed
ACEi or ARB exposure – 
unadjusted analysis
0.760 (0.635-0.910) 0.003 0.968 (0.906-1.033) 0.32
ACEi or ARB exposure – adjusted analysis* 0.707 (0.585-0.853) <0.001  0.797 (0.743-0.855) <0.001
Cumulative exposure (time-dependent analysis) 
Unadjusted analysis ACEi or ARB exposure (per year of exposure) 0.983 (0.977-0.990) <0.001 0.982 (0.979-0.985) <0.001
Ever exposed to ACEi or ARB 0.903 (0.747-1.091) 0.29 1.081 (1.010-1.157) 0.024
Adjusted analysis ACEi or ARB exposure (per year of exposure) 0.988 (0.982-0.994) <0.001 0.986 (0.983-0.989) <0.001
Ever exposed to ACEi or ARB 0.788 (0.647-0.959) 0.017 0.862 (0.802-0.926) <0.001
*adjusted for age, sex, deprivation, comorbidities, previous hip fracture, creatinine, bisphosphonate therapy, calcium and vitamin D therapy, receipt of care package; ACEi: Angiotensin 
converting enzyme inhibitor. ARB: Angiotensin receptor blocker
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in linked, routinely collected clinical data and have all been 
shown to influence the risk of hip fracture or the risk of death. 
We also conducted exploratory subgroup analyses for age 
(above and below median for the study population), sex, and the 
presence of a package of social care as a surrogate for frailty. 
All analyses were conducted in SPSS v24 (IBM, New York, 
USA) with the exception of competing risks analyses, which 
were conducted using the stccreg function in STATA version 
14 (STATAcorp, Texas, USA). A two-sided p value of <0.05 
was taken as significant for all analyses.
Results
A total of 16782 patients were included in the analysis. 
The mean age was 74.2 years and 9957 (59%) were female. 
8354 (50%) had been exposed to ACEi/ARB therapy at any 
point prior to death, fracture or censoring. Table 1 shows 
the baseline details of the cohort. Users of ACEi/ARB were 
more likely to be male, had more comorbid disease, and were 
more likely to be in receipt of a care package than those who 
had never used ACEi or ARB. Table 2 shows the risk of hip 
fracture and of death in unadjusted and adjusted analyses. 
Analyses of any exposure to ACEi/ARB and time-dependent 
analyses accounting for cumulative exposure to ACEi/ARB 
are presented, showing that in adjusted analyses, cumulative 
exposure to ACEi or ARB was associated with an exposure-
dependent reduction in the risk of hip fracture, and that this 
effect was in addition to the lower risk of hip fracture seen in 
those that had previously used ACEi or ARB. Similar, but more 
marked effects were seen for all-cause mortality. Unadjusted 
competing-risks models showed a hazard ratio for hip fracture 
of 0.992 (95%CI 0.986 to 0.998; p=0.006) per year of exposure 
to ACEi/ARB; in adjusted competing-risks analyses, the effect 
did not reach significance (HR 0.996; 95%CI 0.991 to 1.002; 
p=0.21).
Exploratory subgroup analyses for age above or below the 
median (74 years), sex, or the presence or absence of a package 
of care are shown in Table 3. The hazard ratio for death per 
year of exposure to ACEi/ARB was lower for those receiving a 
package of care, and this difference was significant (p=0.03) on 
formal interaction testing; no other significant differences were 
seen between subgroups.
Discussion
In this analysis, exposure to ACEIs/ARBs was associated 
with an exposure-dependent reduction in the risk of hip 
fractures and death. The analysis sample reflects a real-world 
sample due to the use of routinely collected data, was able 
to use time-dependent exposure to medication, and was also 
able to adjust for a range of comorbidities, biomarkers, and 
importantly, was able to adjust for daily function using a proxy 
measure (the need for social care). The results are in accord 
with the majority of previous observational studies (6-13), 
and are also supported by findings from the Hypertension in 
the Very Elderly (HYVET) trial, which found a lower rate 
of fractures in older people with hypertension treated with 
thiazides and ACE inhibitors (16), but differ from a post-hoc 
analysis of the Antihypertensive and Lipid Lowering to prevent 
Heart Attack (ALLHAT) trial, where ACEi did not confer a 
lower risk of fracture compared to calcium channel blockers, 
and were inferior to thiazides (17). Given the known beneficial 
effects of thiazides on bone mineral density, these results are 
not incompatible however. Recent observational data from the 
Womens Health Initiative studies suggests variable risk with 
time; short-term increased risks may be balanced by longer-
term benefits to ACEi use (18).
ACE inhibitors may reduce fracture rates via a range of 
different biological mechanisms. Although such medications 
are often stopped in patients with orthostatic hypotension, 
the evidence that modern, long-acting ACEi and ARBs cause 
orthostatic hypotension is very limited (19); the underlying 
vascular disease that such agents are used to treat is as likely 
to explain any such association in observational studies. On 
the contrary, ACEi and ARB are known to improve endothelial 
function and vascular stiffness (20, 21), and thus could in 
Table 3
Exploratory subgroup analyses – effect of cumulative exposure in adjusted time-dependent analyses
Hip fracture Hazard ratio 
(95% CI)*
P All-cause death
Package of care Yes 0.988 (0.973-1.004 0.13 0.979 (0.960-0.998) 0.032
No 0.987 (0.981-0.994) <0.001 0.986 (0.983-0.989) <0.001
Age >=74 years 0.990 (0.981-0.998) 0.014 0.985 (0.981-0.990) <0.001
<74 years 0.983 (0.974-0.992) <0.001 0.986 (0.982-0.990) <0.001
 Sex Male 0.978 (0.962-0.994) 0.008 0.986 (0.981-0.991) <0.001
Female 0.990 (0.984-0.997) 0.003 0.986 (0.982-0.990) <0.001
Adjusted for age, sex, deprivation, comorbidities, previous hip fracture, creatinine, bisphosphonate therapy, calcium and vitamin D therapy, receipt of care package with the exception of 
the subgroup variable under test; *Hazard ratio per year of ACEi/ARB exposure
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fact mediate improvements in vascular tone and control that 
would mitigate orthostatic hypotension. ACEi have also 
been postulated to directly improve skeletal muscle function; 
observational data suggests that those taking ACEi exhibit 
slower declines in walk speed, and 20 weeks of ACEi therapy 
improved six-minute walk distance in older people with 
functional impairment (2). ACEi do not appear to improve 
postural sway in older people at risk of falls however (4). 
Finally, it is possible that ACEi and ARB may have beneficial 
effects on bone mineral density, although observational studies 
to date suggest that this benefit may be confined to African-
American men (22, 23).
Observational studies cannot ascertain causality, even with 
adjustment for multiple confounders, and our findings may still 
be due to residual confounding. We could not adjust directly 
for frailty, but relied on a surrogate measure of functional 
impairment. We did not compare the effect of ACEi/ARB 
use with use of other classes of antihypertensive medication, 
although dissecting out effects for different classes in patients 
on multiple medications would be challenging. We were also 
unable to adjust for some important covariates, such as blood 
pressure, as these data were not available in electronic form 
in the routinely collected datasets available for this analysis. 
Similarly, data on cognition were not available in electronic 
form, and would not have been recorded as part of routine care 
for many of those studied in this analysis. Some diagnoses, 
such as a diagnosis of hypertension, are not well recorded on 
hospital discharge codes and we could not therefore adjust 
for such covariates. Despite these limitations, our findings, in 
conjunction with previous observational and trial evidence, 
at least call into question the appropriateness of avoiding or 
discontinuing ACEi/ARBs in older people at risk of falls and 
fracture.
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